Bedros Bakirtzian, MD
Orthopaedic Surgery · Massena, NYNPI 1124026372
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $486 of the $675 with a category attached, or 72.0%. 6 manufacturers reported payments, led by Treace Medical Concepts, Inc. at 43.4% of the total. Reporting peaked in 2024 at $191 and has fallen 63.3% since, to $70 in 2025. That places this record below the midpoint for orthopaedic surgery clinicians in NY, where the typical reported total is $4,024.
Across 19 payments — averaging $35.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Treace Medical Concepts, Inc.$293
- Davol Inc.$129
- Prodigy Surgical Distribution, Inc.$98
- Zimmer Biomet$91
- Smith+Nephew$48
- Amgen$16
Across 14 payments — averaging $319,266 each. An ownership or investment interest held by the physician or an immediate family member.
- Intellijoint Surgical Inc.$4.5M
What the payments were for
- Food & beverage$48672%
- Education$18928%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Treace Medical Concepts, Inc. | 11 | $293 |
| Davol Inc. | 3 | $129 |
| Prodigy Surgical Distribution, Inc. | 1 | $98 |
| Zimmer Biomet | 1 | $91 |
| Smith+Nephew | 2 | $48 |
| Amgen | 1 | $16 |
How this compares
$675 in reported general payments places this provider in the 25th percentile of 1,079 orthopaedic surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 172 | $3,323 |
| Meloxicam | 168 | $439 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 68 | $404 |
| Naproxen | 16 | $281 |
| Ibuprofen | 15 | $232 |
| Gabapentin | 25 | $88 |
| Cephalexin | 19 | $76 |
| Methocarbamol | 13 | $69 |
| Ciprofloxacin Hcl | 26 | $52 |
| Tramadol Hcl | 13 | $44 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Massena
- Anthony RomeoNew York$26.8M
- Lawrence LenkeNew York$26.8M
- Edwin SuNew York$13.2M
- William RicciNew York$11.6M
- Steven HaasNew York$11.3M
- Giles ScuderiNew York$10.7M
- Joseph ZuckermanNew York$9.9M
- Evan FlatowNew York$9.6M
- Bradford ParsonsNew York$9.4M
- Geoffrey WestrichNew York$7.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.